Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 229-242

  Burdick, Michael J ^a   Macklis, Roger M ^a,b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Bexxar; Non Hodgkin's lymphoma; Radioimmunotherapy; Tositumomab

Indexed keywords

ADRENALIN; ANTHRACYCLINE; CARMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIPHENHYDRAMINE; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IODINE 131; LUGOL; MELPHALAN; PARACETAMOL; PLATINUM; POTASSIUM IODIDE; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGY; ANAPHYLAXIS; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CLINICAL EFFECTIVENESS; DIAPHORESIS; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG USE; DYSPNEA; FEVER; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; HYPOTHYROIDISM; KARNOFSKY PERFORMANCE STATUS; KIDNEY DISEASE; LEUKOPENIA; LIPID RAFT; LIVER DISEASE; LOW ENERGY RADIATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; NONHUMAN; PREGNANCY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; RIGOR; SEROCONVERSION; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME; WHOLE BODY RADIATION;

EID: 77953451773     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Fisher RI. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol. 2003;30(2 Suppl 4):3-9. (Pubitemid 36505462)
3. Traweek ST, Liu J, Johnson RM, Winberg CD, Rappaport H. High-grade transformation of chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Genotypic confirmation of clonal identity. Am J Clin Pathol. 1993;100(5):519-526. (Pubitemid 23346200)
4. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-1652. (Pubitemid 28110329)
5. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-1052.
6. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
7. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-4177.
8. Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480-5489. (Pubitemid 37139867)
9. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7):2738-2743.
10. Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res. 2008;14(15):4925-4934.
11. 131I Tositumomab): Prescribing Information. October 2005:1-33. http://www.bexxar.com/ . Accessed July 27, 2009.
12. Silberstein EB, Alavi A, Balon HR, DVB. Society of Nuclear Medicine Procedure Guideline for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide) version 2.0. September 9, 2005:1-8. http://interactive.snm.org/index. cfm?PageID=772&RPID=969. Accessed July 27, 2009.
13. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10(23):7792-7798.
14. Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79(9):493-500. (Pubitemid 30739545)
15. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195. (Pubitemid 27392702)
16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
17. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm. 2003;18(4):513-524. (Pubitemid 37082370)
18. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(27):4418-4425. (Pubitemid 46646247)
19. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18(6):1316-1323. (Pubitemid 30159851)
20. 131I tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22(8):1469-1479.
21. Mones JV, Coleman M, Kostakoglu L, et al. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leuk Lymphoma. 2007;48(2):342-348. (Pubitemid 46994884)
22. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329(7):459-465.
23. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44(2):260-268.
24. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14(7):1974-1981.
25. 131I) tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259-1266.
26. 131I tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19(19):3918-3928.
27. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5):441-449. (Pubitemid 40175970)
28. Nordoy T, Kolstad A, Tuck MK, Aaberge IS, Husebekk A, Kaminski MS. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol. 2001;100(1):40-48. (Pubitemid 32607239)
29. 131I tositumomab. Blood. 2005;105(12):4576-4582.
30. 131I- tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 years. J Clin Oncol. 2007:8033.
31. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23(4):712-719. (Pubitemid 46224170)
32. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23(30):7565-7573.
33. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23(31):7985-7993.
34. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006;106(3):616-622. (Pubitemid 43157625)
35. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329(17):1219-1224. (Pubitemid 23306322)
36. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346(8971):336-340.
37. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16(10):3270-3278.
38. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96(9):2934-2942. (Pubitemid 30815198)
39. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102(7):2351-2357.
40. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99(9):3158-3162. (Pubitemid 34525293)
41. 131I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25(11):1396-1402.
42. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(3):461-467. (Pubitemid 46224222)
43. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24(25):4143-4149.
44. 131I tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23(24):5696-5704.
45. 131I tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol (Meeting Abstracts). 2004;22:6520.
46. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008;112(3):830-835.
47. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
48. 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med. 2000;41(6):999-1005.
49. Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009;50(1):8-17.
50. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226(4678):1097-1099. (Pubitemid 15217831)
51. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
52. Garber K. Users fear that lymphoma drugs will disappear. J Natl Cancer Inst. 2007;99(7):498-499, 501.
53. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27(10):1607-1614.
54. Hagenbeek A. Maintenance or eradication of residual disease in indolent lymphoma: where do we stand? J Clin Oncol. 2009;27(10):1540-1542.
55. Plastaras JP, Glatstein E, Schuster SJ. Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma. Oncologist. 2008;13(6):655-656. (Pubitemid 351904910)